WeightWatchers, a pioneer in the diet industry for six decades, is making a strategic move to cater to the evolving needs of individuals relying on Ozempic and Wegovy.
Ozempic and Wegovy Users Benefit from WeightWatchers’ Tailored Weight-Loss Program (Photo: Yahoo Finance)
Impact of Ozempic and Wegovy on the Diet Landscape
In a report featured by CBS News, in december 15, 2023, contrary to initial expectations that the popularity of Ozempic, a semaglutide-based diabetes drug, would overshadow traditional diet programs, WeightWatchers has responded innovatively. The company recently unveiled the WeightWatchers GLP-1 Program, a subscription service tailored to the health and nutrition requirements of individuals using Ozempic and Wegovy. This initiative signifies a proactive effort by the 60-year-old diet company to stay pertinent in an industry undergoing rapid transformations due to the widespread use of these revolutionary medications.
The surge in the adoption of Ozempic and Wegovy, both semaglutide derivatives, has disrupted the diet industry and prompted substantial shifts in consumer eating habits. As these medications gain popularity for their effectiveness in weight loss, a Morgan Stanley Research report estimates that by 2035, approximately 24 million people, constituting 7% of the U.S. population, could be utilizing these drugs.
Recognizing this transformative trend, WeightWatchers aims to address the unique challenges faced by individuals on GLP-1 medications through its specialized program. The introduction of the WeightWatchers GLP-1 Program aligns with the company’s commitment to helping members establish and adhere to healthy habits while steering the changes induced by Ozempic and Wegovy.
READ ALSO: Tensions Are At An All-Time High As Biden Criticizes Israeli Actions In Gaza
Meeting Unique Challenges: The WeightWatchers GLP-1 Program
In a recent news released by Yahoo Finance, developed by a team of experts, including scientists, dietitians, and fitness professionals specializing in obesity, the WeightWatchers GLP-1 Program is designed to guide members through the complexities of incorporating anti-obesity medications such as Ozempic and Wegovy into their weight loss journey. The program recognizes that those on GLP-1 medications, experiencing reduced appetite and significant weight loss, require support tailored to their distinct behavioral challenges.
In addition to daily nutrition and activity targets, the program emphasizes weight training to help subscribers preserve muscle mass while shedding pounds. By focusing on dietary protein and activity, the WeightWatchers GLP-1 Program aims to minimize the loss of muscle mass, ensuring a holistic and sustainable approach to weight management for Ozempic and Wegovy users.
READ ALSO: Energy Experts Criticize The UN Deal To Phase Out Fossil Fuels
